Nature Communications (Sep 2017)
Hepcidin is regulated by promoter-associated histone acetylation and HDAC3
- Sant-Rayn Pasricha,
- Pei Jin Lim,
- Tiago L. Duarte,
- Carla Casu,
- Dorenda Oosterhuis,
- Katarzyna Mleczko-Sanecka,
- Maria Suciu,
- Ana Rita Da Silva,
- Kinda Al-Hourani,
- João Arezes,
- Kirsty McHugh,
- Sarah Gooding,
- Joe N. Frost,
- Katherine Wray,
- Ana Santos,
- Graça Porto,
- Emmanouela Repapi,
- Nicki Gray,
- Simon J. Draper,
- Neil Ashley,
- Elizabeth Soilleux,
- Peter Olinga,
- Martina U. Muckenthaler,
- Jim R. Hughes,
- Stefano Rivella,
- Thomas A. Milne,
- Andrew E. Armitage,
- Hal Drakesmith
Affiliations
- Sant-Rayn Pasricha
- MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford
- Pei Jin Lim
- MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford
- Tiago L. Duarte
- Instituto de Investigação e Inovação em Saúde and IBMC—Instituto de Biologia Molecular e Celular, University of Porto
- Carla Casu
- Division of Hematology, Department of Pediatrics, Children’s Hospital of Philadelphia
- Dorenda Oosterhuis
- Pharmaceutical Technology and Biopharmacy, Department of Pharmacy, University of Groningen
- Katarzyna Mleczko-Sanecka
- Department of Pediatric Hematology, Oncology and Immunology, University of Heidelberg; and Molecular Medicine Partnership Unit
- Maria Suciu
- MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford
- Ana Rita Da Silva
- Department of Pediatric Hematology, Oncology and Immunology, University of Heidelberg; and Molecular Medicine Partnership Unit
- Kinda Al-Hourani
- MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford
- João Arezes
- MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford
- Kirsty McHugh
- Jenner Institute, University of Oxford
- Sarah Gooding
- MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford
- Joe N. Frost
- MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford
- Katherine Wray
- MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford
- Ana Santos
- Instituto de Investigação e Inovação em Saúde and IBMC—Instituto de Biologia Molecular e Celular, University of Porto
- Graça Porto
- Instituto de Investigação e Inovação em Saúde and IBMC—Instituto de Biologia Molecular e Celular, University of Porto
- Emmanouela Repapi
- Computational Biology Research Group, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital
- Nicki Gray
- Computational Biology Research Group, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital
- Simon J. Draper
- Jenner Institute, University of Oxford
- Neil Ashley
- MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford
- Elizabeth Soilleux
- Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, Oxford University
- Peter Olinga
- Pharmaceutical Technology and Biopharmacy, Department of Pharmacy, University of Groningen
- Martina U. Muckenthaler
- Department of Pediatric Hematology, Oncology and Immunology, University of Heidelberg; and Molecular Medicine Partnership Unit
- Jim R. Hughes
- MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford
- Stefano Rivella
- Division of Hematology, Department of Pediatrics, Children’s Hospital of Philadelphia
- Thomas A. Milne
- MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford
- Andrew E. Armitage
- MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford
- Hal Drakesmith
- MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford
- DOI
- https://doi.org/10.1038/s41467-017-00500-z
- Journal volume & issue
-
Vol. 8,
no. 1
pp. 1 – 15
Abstract
Hepcidin controls systemic iron levels by inhibiting intestinal iron absorption and iron recycling. Here, Pasricha et al. demonstrate that the hepcidin-chromatin locus displays HDAC3-mediated reversible epigenetic modifications during both erythropoiesis and iron deficiency.
